<DOC>
	<DOCNO>NCT01066611</DOCNO>
	<brief_summary>The purpose study determine safety effect CAL-263 subject allergic rhinitis .</brief_summary>
	<brief_title>Study Investigate Effects CAL-263 Subjects With Allergic Rhinitis Exposed Allergen Environmental Chamber</brief_title>
	<detailed_description>A Phase I , randomize , double-blind crossover study CAL-263 , oral inhibitor PI3K delta , patient allergic rhinitis .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 55 year 2 . Has history seasonal allergic rhinitis least 2 year 3 . Has sensitivity grass pollen demonstrate positive response skin prick test 4 . Has positive Radio Allergen Sorbent Test ( class 2 great ) grass pollen previous 12 month screen 5 . Is otherwise healthy 6 . Is able provide write informed consent 1 . Is female childbearing 2 . History chronic nasal upper respiratory tract symptoms disorder allergic rhinitis 3 . History nonallergic rhinitis , chronic sinusitis severe asthma 4 . Has nasal condition likely affect outcome study 5 . Is currently take regular medication , whether prescribe , include corticosteroid , vitamin , macrolides , antifungal agent herbal remedy 6 . Has take prohibit medication within specify interval prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Phosphatidylinositol 3-kinase</keyword>
</DOC>